
浏览全部资源
扫码关注微信
1.上海中医药大学附属市中医医院肿瘤临床医学中心(上海 200071)
2.上海市中医医院肿瘤研究所 (上海 200071)
罗斌,男,博士,主治医师,主要从事中医药调控免疫防治恶性肿瘤的临床与基础研究工作
田建辉,主任医师,博士研究生导师;E-mail: tjhhawk@163.com
李雁,主任医师,博士研究生导师; E-mail: yan.xiaotian@shutcm.edu.cn
收稿:2025-10-17,
网络首发:2026-08-03,
纸质出版:2026-08-10
移动端阅览
罗斌,田建辉,阙祖俊,等.正虚伏毒:从理论到临床的中医肿瘤防治创新实践[J].上海中医药杂志,2026,60(8):43-48.
Luo Bin,Tian Jianhui,Que Zujun,et al.Latent toxicity due to vital qi deficiency: innovative practices in traditional Chinese medicine oncology from theory to clinical[J].Shanghai Journal of Traditional Chinese Medicine,2026,60(8):43-48.
罗斌,田建辉,阙祖俊,等.正虚伏毒:从理论到临床的中医肿瘤防治创新实践[J].上海中医药杂志,2026,60(8):43-48. DOI: 10.16305/j.1007-1334.2026.z20251017002.
Luo Bin,Tian Jianhui,Que Zujun,et al.Latent toxicity due to vital qi deficiency: innovative practices in traditional Chinese medicine oncology from theory to clinical[J].Shanghai Journal of Traditional Chinese Medicine,2026,60(8):43-48. DOI: 10.16305/j.1007-1334.2026.z20251017002.
研究团队聚焦肿瘤转移的科学难题,以跨界交叉方式融合现代技术与中医药理论,创建核心病机正虚伏毒理论,并在基础研究到临床转化过程中不断创新发展,深入探究正虚与免疫系统等的紊乱关联、伏毒涵盖多种肿瘤细胞类型等理论内涵,揭示正虚与伏毒二者致病恶性循环机制;并据此将肿瘤术后复发转移的防治分为3个阶段,提出对应的中医药干预策略,探索出一种独特的中医理论融合创新发展模式。
Research team addresses the scientific challenge of tumor metastasis by integrating modern technology with traditional Chinese medicine(TCM)principles through interdisciplinary methodologies. They have developed the core pathogenesis theory of "latent toxicity due to vital qi deficiency," which has been progressively refined through translational research from bench to bedside. Comprehensive studies have investigated the theoretical implications, such as the relationship between systemic deficiency and immune dysregulation, as well as the role of "latent toxin" in various tumor cell types, elucidating a vicious cycle that exacerbates disease malignancy. Building on this foundation, they have delineated the prevention of postoperative recurrence and metastasis into three distinct stages, for which they propose specific TCM intervention strategies and explore a unique model for the integration and innovative development of TCM theory.
郑荣寿 , 陈茹 , 韩冰峰 , 等 . 2022年中国恶性肿瘤流行情况分析 [J]. 中华肿瘤杂志 , 2024 , 46 ( 3 ): 221 - 231 .
赵丹丹 , 何萍 , 夏寒 , 等 . 基于真实世界临床数据的恶性肿瘤流行病学调查研究 [J]. 上海医学 , 2023 , 46 ( 7 ): 493 - 497 .
Temel J S , Petrillo L A , Greer J A . Patient-centered palliative care for patients with advanced lung cancer [J]. J Clin Oncol , 2022 , 40 ( 6 ): 626 - 34 .
田建辉 , 罗斌 , 阙祖俊 , 等 . 中西医结合视域下肿瘤转移态学说的初步构建 [J]. 中医杂志 , 2024 , 65 ( 20 ): 2065 - 2069 .
袁伟琛 , 周红光 , 李文婷 , 等 . 中医药防治恶性肿瘤的现状、优势及策略 [J]. 南京中医药大学学报 , 2025 , 41 ( 6 ): 707 - 720 .
Xi Z , Dai R , Ze Y , et al . Traditional Chinese medicine in lung cancer treatment [J]. Mol Cancer , 2025 , 24 ( 1 ): 57 .
刘嘉湘 , 田建辉 . 传承中医药学术精华,促进肿瘤学创新发展 [J]. 上海中医药杂志 , 2020 , 54 ( 7 ): 29 - 33 .
田建辉 . “正虚伏毒”为肺癌发病的核心病机 [J]. 上海中医药杂志 , 2016 , 50 ( 12 ): 10 - 14 .
田建辉 , 罗斌 , 阙祖俊 , 等 . 癌症转移亚临床阶段核心病机“正虚伏毒”学说 [J]. 上海中医药杂志 , 2021 , 55 ( 10 ): 1 - 3,13 .
陈腾飞 , 刘清泉 . 浅述中医“正气”理论 [J]. 环球中医药 , 2016 , 9 ( 11 ): 1332 - 1335 .
沈自尹 . “肾的研究”通过“与时俱进”而不断进取 [J]. 中国中西医结合杂志 , 2015 , 35 ( 8 ): 946 - 949 .
刘嘉湘 . 扶正治癌融汇中西继承创新 [J]. 中国中西医结合杂志 , 2019 , 39 ( 1 ): 10 - 12 .
方心怡 , 苗润宇 , 魏佳华 , 等 . 现代组学技术在中医证候研究的进展 [J]. 中华中医药学刊 , 2023 , 41 ( 9 ): 132 - 137 .
Liu L , Chen A , Li Y , et al . Spatiotemporal omics for biology and medicine [J]. Cell , 2024 , 187 ( 17 ): 4488 - 4519 .
王琦 . 中医基础理论的重构与时代发展 [J]. 中华中医药杂志 , 2023 , 38 ( 1 ): 11 - 17 .
Que Z , Luo B , Zhou Z , et al . Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo [J/OL]. Cancer Cell Int , 2019-01-29 . https://pubmed.ncbi.nlm.nih.gov/30718976/ https://pubmed.ncbi.nlm.nih.gov/30718976/ .
Luo B , Wang P , Tian J , et al . Jinfukang inhibits lung cancer metastasis by regulating T cell receptors [J]. J Ethnopharmacol , 2024 , 318 ( Pt A ): 116885 .
Que Z , Xi Z , Qi D , et al . Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: A promising therapeutic target [J]. Sci Adv , 2025 , 11 ( 28 ): eadv7377 .
Que Z , Qi D , Yang Y , et al . Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters [J]. Cell Mol Biol Lett , 2025 , 30 ( 1 ): 23 .
Kyrysyuk O , Wucherpfennig K W . Designing cancer immunotherapies that engage T cells and NK cells [J]. Annu Rev Immunol , 2023 , 41 : 17 - 38 .
O'Donnell J S , Teng M W L , Smyth M J . Cancer immunoediting and resistance to T cell-based immunotherapy [J]. Nat Rev Clin Oncol , 2019 , 16 ( 3 ): 151 - 167 .
Lasser S A , Ozbay Kurt F G , Arkhypov I , et al . Myeloid-derived suppressor cells in cancer and cancer therapy [J]. Nat Rev Clin Oncol , 2024 , 21 ( 2 ): 147 - 164 .
Roerden M , Spranger S . Cancer immune evasion, immunoediting and intratumour heterogeneity [J]. Nat Rev Immunol , 2025 , 25 ( 5 ): 353 - 369 .
Boutilier A J , Elsawa S F . Macrophage polarization states in the tumor microenvironment [J]. Int J Mol Sci , 2021 , 22 ( 13 ): 6995 .
孙晓荷 , 李柳 , 王俊壹 , 等 . 基于癌毒病机理论探讨恶性肿瘤癌变病机特点 [J]. 中华中医药杂志 , 2025 , 40 ( 4 ): 1651 - 1654 .
王晓群 , 李玉婷 , 赵林林 , 等 . 贾英杰“黜浊培本”治疗恶性肿瘤学术探讨 [J]. 中医杂志 , 2021 , 62 ( 7 ): 568 - 571 .
田建辉 , 罗斌 . 肺癌“正虚伏毒”病机的生物学基础(二)——基于隐匿性肿瘤细胞之肺癌“伏毒”病机探要 [J]. 上海中医药杂志 , 2018 , 52 ( 2 ): 6 - 10 .
Lin D , Shen L , Luo M , et al . Circulating tumor cells: biology and clinical significance [J]. Signal Transduct Target Ther , 2021 , 6 ( 1 ): 404 .
Wang Y , Jia J , Wang F , et al . Pre-metastatic niche: formation, characteristics and therapeutic implication [J]. Signal Transduct Target Ther , 2024 , 9 ( 1 ): 236 .
Li Y , Liu F , Cai Q , et al . Invasion and metastasis in cancer: molecular insights and therapeutic targets [J]. Signal Transduct Target Ther , 2025 , 10 ( 1 ): 57 .
Derynck R , Akhurst R J , Balmain A . TGF-β signaling in tumor suppression and cancer progression [J]. Nat Genet , 2001 , 29 ( 2 ): 117 - 129 .
Zhang Y E , Stuelten C H . Alternative splicing in EMT and TGF-β signaling during cancer progression [J]. Semin Cancer Biol , 2024 , 101 : 1 - 11 .
Zhang R , Dong M , Tu J , et al . PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway [J]. Signal Transduct Target Ther , 2023 , 8 ( 1 ): 97 .
李潇 , 王黎 . 髓源性抑制细胞的免疫调节作用及对肿瘤治疗的影响 [J]. 上海交通大学学报(医学版) , 2019 , 39 ( 10 ): 1204 - 1208 .
Yu S , Gan C , Li W , et al . Depression decreases immunity and PD-L1 inhibitor efficacy via the hypothalamic-pituitary-adrenal (HPA) axis in triple-negative breast cancer [J]. Biochim Biophys Acta Mol Basis Dis , 2025 , 1871 ( 2 ): 167581 .
董昌盛 , 阙祖俊 , 朱丽华 , 等 . 基于循环肿瘤细胞的非小细胞肺癌之“伏毒”本质临证探析 [J]. 上海中医药大学学报 , 2018 , 32 ( 1 ): 18 - 22 .
罗伟仁 . 重新思考肿瘤 [J]. 中华肿瘤杂志 , 2025 , 47 ( 6 ): 463 - 467 .
Luca B A , Steen C B , Matusiak M , et al . Atlas of clinically distinct cell states and ecosystems across human solid tumors [J]. Cell , 2021 , 184 ( 21 ): 5482 - 5496 .
Que Z , Luo B , Yu P , et al . PolyphyllinⅦ induces CTC anoikis to inhibit lung cancer metastasis through EGFR pathway regulation [J]. Int J Biol Sci , 2023 , 19 ( 16 ): 5204 - 5217 .
徐力立 , 李雁 , 蒋雷 , 等 . 扶正祛邪方防治ⅠB~ⅡB期非小细胞肺癌复发转移及对体液免疫功能影响的临床研究 [J]. 上海中医药杂志 , 2024 , 58 ( 12 ): 119 - 124 .
陈皖晴 , 张博 , 许荣忠 , 等 . 不同治法方药对早期非小细胞肺癌术后患者免疫功能及预后的影响 [J]. 时珍国医国药 , 2022 , 33 ( 4 ): 899 - 901 .
李佳轩 , 罗斌 , 冯茜 , 等 . 田建辉治疗恶性肿瘤及其合并症常用药对-药组撷菁 [J]. 上海中医药杂志 , 2024 , 58 ( 12 ): 95 - 99 .
赵外荣 , 杨蕴 , 姚嘉良 , 等 . “导引调神”对肺癌患者心肺耐力及情绪的影响 [J]. 山东中医杂志 , 2024 , 43 ( 11 ): 1178 - 1187 .
李金根 , 徐浩 . 构建中西医结合精准医学新模式:理论提出与实践 [J]. 科学通报 , 2025 , 70 ( 35 ): 5949 - 5955 .
骆长永 , 刘智 , 于河 , 等 . 钱学森系统工程体系在名老中医经验传承中的应用模式解析 [J]. 中国中医基础医学杂志 , 2023 , 29 ( 11 ): 1855 - 1858 .
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构
沪公网安备 31011502015228号